Skip to main content
OpenTrials
Completed

NCT Number: NCT03107013

A Study to Investigate the Mass Balance of BTD-001

This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Quotient Clinical

Ruddington, NG11 6JS, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult males aged 30-65 years old
  • BMI between18.0-35.0 kg/m2 unless investigator deems not clinically significant
  • Regular daily bowel movements
  • Provide written consent
  • Agrees to protocol specified contraception

Exclusion criteria

  • Received any investigational treatment within last 3 months
  • Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  • Subjects who have previously been enrolled in this study
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week
  • Current smokers and those who have smoked, including nicotine replacement or e-cigarates within the last 12 months.
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  • Clinically significant abnormal lab results
  • Positive drugs of abuse test result
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  • Evidence of renal impairment at screening
  • History of or current seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years
  • Clinically significant medical/psychiatric history findings, or physical/neurological examination findings or significant history of or current suicidal ideation or behaviour
  • History of or current significant pulmonary, cardiac, renal, hepatic, chronic respiratory, gastrointestinal, neurological or psychiatric disease, substance dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal cell carcinomas or local cervical squamous cell cancer resolved after resection) or hypothyroidism
  • Subjects with QT interval corrected for heart rate according to Fridericia's formula >450 msec
  • Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol) or herbal remedies
  • Failure to satisfy the investigator of fitness to participate for any other reason

Treatment and study plan

[14C]-BTD-001

Drug

Carbon-14 labeled BTD-001

Primary outcomes

  1. Mass balance recovery after a single dose of carbon-14 (14C)-BTD-001

    Time frame: Maximum 12 days

    The percentage of radioactive dose of [14C] radiolabelled BTD-001 recovered in urine, faeces, and plasma

  2. Metabolite Profiling

    Time frame: Maximum 12 days

    To provide plasma, urine and faecal samples for metabolite profiling and structural identification

Secondary outcomes

  1. Determination of routes and rates of elimination of [14C]-BTD-001

    Time frame: Maximum 12 days

    [14C]-BTD-001 metabolite profiling and structural identification in plasma, urine and faeces

  2. Determination of the chemical structure of the "major" metabolites of [14C]-BTD-001

    Time frame: Maximum 12 days

    Identification of the chemical structure of each metabolite accounting for more than 10% (by AUC) of circulating total radioactivity

  3. Evaluation of whole blood:plasma concentration ratios for total radioactivity

    Time frame: Maximum 12 days

    To evaluate the extent of distribution of total radioactivity into blood cells

  4. physical examination

    Time frame: Maximum 12 days

    Safety and tolerability of BTD-001 by assessing physical examination

  5. safety laboratory tests

    Time frame: Maximum 12 days

    Safety and tolerability of BTD-001 by assessingsafety laboratory tests and AEs

  6. Vital signs

    Time frame: Maximum 12 days

    Safety and tolerability of BTD-001 by assessing vital signs

  7. ECGs

    Time frame: Maximum 12 days

    Safety and tolerability of BTD-001 by assessing ECGs

  8. AEs

    Time frame: Maximum 12 days

    Safety and tolerability of BTD-001 by assessing physical examination AEs

Other outcomes

  1. Cmax

    Time frame: Maximum 12 days

    Maximum Observed Plasma Concentration

  2. tmax

    Time frame: Maximum 12 days

    time to reach maximum concentration

  3. t1/2

    Time frame: Maximum 12 days

    elimination half-life

Sponsors and collaborators

Lead sponsor

Balance Therapeutics

Industry

Registry information

Official study title

An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects

Acronym: HV103

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Apr 11, 2017
Registry last updated
Oct 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.